Cargando…

Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study

SIMPLE SUMMARY: Immune checkpoint inhibition plays a pivotal role in the treatment of metastatic renal cell carcinoma and metastatic urothelial carcinoma. The association of chronic kidney disease with these tumors is well established. However, to what extent kidney failure modifies the efficacy or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seydel, Florian, Delecluse, Susanne, Zeier, Martin, Holland-Letz, Tim, Haag, Georg Martin, Berger, Anne Katrin, Grün, Barbara Christine, Bougatf, Nina, Hohenfellner, Markus, Duensing, Stefan, Jäger, Dirk, Zschäbitz, Stefanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036307/ https://www.ncbi.nlm.nih.gov/pubmed/33915693 http://dx.doi.org/10.3390/cancers13071623

Ejemplares similares

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
por: Li, Jielin, et al.
Publicado: (2021)

Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma
por: Schneider, Felix, et al.
Publicado: (2023)

Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers
por: Zschäbitz, Stefanie, et al.
Publicado: (2017)

Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease
por: Zschäbitz, Stefanie, et al.
Publicado: (2018)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

Prospective single center trial of next-generation sequencing analysis in metastatic renal cell cancer: the MORE-TRIAL
por: Dieffenbacher, Svenja, et al.
Publicado: (2018)

BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study
por: Friedhoff, Jana, et al.
Publicado: (2022)

Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

eHealth intervention to manage symptoms for patients with cancer on immunotherapy (SOFIA): a study protocol for a randomised controlled external pilot trial
por: Sauer, Christina, et al.
Publicado: (2021)

Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder
por: Tosev, Georgi, et al.
Publicado: (2021)

The BRCA2 mutation status shapes the immune phenotype of prostate cancer
por: Jenzer, Maximilian, et al.
Publicado: (2019)

Concomitant Urothelial Cancer and Renal Tuberculosis
por: Chin, Sheray N., et al.
Publicado: (2014)

Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient
por: Berger, Anne Katrin, et al.
Publicado: (2017)

Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability
por: Tapia-Laliena, María Ángeles, et al.
Publicado: (2019)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Recurrent papillary renal cell carcinoma with concomitant ipsilateral upper urinary tract urothelial carcinoma and metachronous urothelial carcinoma of the bladder
por: Banapour, Pooya, et al.
Publicado: (2018)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Vaginal cancer treated with curative radiotherapy with or without concomitant chemotherapy: oncologic outcomes and prognostic factors
por: Meixner, Eva, et al.
Publicado: (2021)

Spontaneous lymphoblastoid cell lines from patients with Epstein-Barr virus infection show highly variable proliferation characteristics that correlate with the expression levels of viral microRNAs
por: Delecluse, Susanne, et al.
Publicado: (2019)

Optimal experimental designs for dose–response studies with continuous endpoints
por: Holland-Letz, Tim, et al.
Publicado: (2014)

Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy
por: Lindner, Andrea Katharina, et al.
Publicado: (2023)

Kidney Cancer Models for Pre-Clinical Drug Discovery: Challenges and Opportunities
por: Pohl, Laura, et al.
Publicado: (2022)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018)

Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma
por: Seront, Emmanuel, et al.
Publicado: (2018)

Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
por: Aicher, Wilhelm K., et al.
Publicado: (2021)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review
por: Walia, Arman S., et al.
Publicado: (2021)

Concomitant Bifocal Urothelial Carcinoma and Breast Tumor: Second Primary Cancer or Metastatic Spread to the Breast?
por: Dumont, Clément, et al.
Publicado: (2014)

Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2018)

Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review
por: Li, Honglin, et al.
Publicado: (2023)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Outlook into the future of front-line immune checkpoint inhibition in metastatic urothelial carcinoma
por: Brown, Jason R., et al.
Publicado: (2021)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dhqebpjfa66gar0rt35hkuu8mm